Regenxbio Inc (FRA:RB0)
€ 11.7 0.2 (1.72%) Market Cap: 582.38 Mil Enterprise Value: 351.37 Mil PE Ratio: 0 PB Ratio: 1.62 GF Score: 65/100

Regenxbio Inc at Morgan Stanley Healthcare Conference Transcript

Sep 10, 2019 / 08:05PM GMT
Release Date Price: €28.74 (-0.03%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

So great. So thanks for staying with us for the next session. I'm Matthew Harrison. I'm the biotech analyst here at Morgan Stanley. Pleased to have REGENX with me for the next session.

Quickly before we get started, I just need to read the disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures, or you can pick up your own very personal copy at the registration desk.

So pleased to have the team from REGENXBIO up here. Ken, I don't know if you want to make any opening remarks before we get started. If you do, happy to have them. If not, I'll just jump right in.

Kenneth T. Mills
REGENXBIO Inc. - CEO, President & Director

Thanks for having us, Matt.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot